U.S. legislators have asked for help to reimagine how the FDA should regulate cannabidiol (CBD) following the agency’s determination that it could not make use of its existing legislative or regulatory authorities to do so. Now, key stakeholders have weighed in, with many telling Congress that FDA’s existing frameworks could be repurposed or refined to regulate CBD effectively, and that a wholesale revamp would be both unnecessary and inefficient. Read on for AgencyIQ’s analysis of key comments and what comes next for FDA, industry and Congress.
Regulatory background: How FDA regulates CBD
Cannabidiol (CBD), a biologically active chemical compound derived from the Cannabis sativa plant, significantly benefited from the passage of the 2018 Farm Bill.
Fill out the form to read the full article.
